miR34a targets multiple oncogenic genes, such as Cluster of Differentiation 44 (CD44) and Mesenchymal–Epithelial Transition factor (c-MET), by suppressing cell proliferation, metastasis, and cancer growth [48,49]. The gene discussed is MET; the disease is cancer.